| 1 |
34729938 | Hexokinases II-mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer. | 2021 Dec |
2 |
| 2 |
33082316 | Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. | 2020 Oct 20 |
2 |
| 3 |
29755689 | A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. | 2018 Apr 17 |
2 |
| 4 |
30466782 | Prolonged MEK inhibition leads to acquired resistance and increased invasiveness in KRAS mutant gastric cancer. | 2018 Dec 9 |
1 |
| 5 |
28845578 | Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review. | 2017 Nov |
2 |
| 6 |
29383132 | Norcantharidin alone or in combination with crizotinib induces autophagic cell death in hepatocellular carcinoma by repressing c-Met-mTOR signaling. | 2017 Dec 29 |
2 |
| 7 |
24556908 | Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer. | 2014 May |
1 |
| 8 |
24929890 | Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. | 2014 Aug |
2 |
| 9 |
25228590 | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. | 2014 Sep 30 |
1 |
| 10 |
22987955 | Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. | 2012 Sep |
1 |